Carnegie Mellon University in Qatar (CMU-Q) and QLife Pharma have signed a memorandum of understanding (MoU) to co-operate in the areas of research, education and the career development of Carnegie Mellon students.
During the ceremony, Dr Ahmed Hamad al-Mohanadi, CEO of QLife Pharma, said: “It is very important that Qatar achieves self-sufficiency in medicine, and that is part of our organisation’s main objective.
We aim to provide high-quality, affordable medication, while serving both the local and global community. Such goals can only be accomplished through collaborations with research and development institutions, which is why our partnership with CMU-Q is such an exciting opportunity.” QLife Pharma is “dedicated to the manufacturing of high-quality products using world-class advanced technology”, a press statement noted.
The first pharmaceutical company in Qatar, QLife Pharma aims to be a “premier, research-intensive pharmaceutical company dedicated to providing leading innovations and solutions”.
Michael Trick, dean of CMU-Q, noted: “The strategic partnership with QLife Pharma is an important one for CMU-Q, particularly for our Biological Sciences Programme. Our students develop very strong laboratory skills beginning in their first semester and exposure to the pharmaceutical industry will serve to broaden their experience and open new career possibilities.”
Gordon Rule, area head of the Biological Sciences Programme at CMU-Q, added: “We train our students to solve real-world problems, which is what makes our partnership with QLife Pharma so important. We can equip our students with the foundation knowledge of how to operate in the industry, but to have access to the industry itself is a first and a wonderful opportunity.”
Carnegie Mellon University in Qatar delivers select programmes that contribute to the long-term development of Qatar.